1. Home
  2. OBK vs AGIO Comparison

OBK vs AGIO Comparison

Compare OBK & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Bancorp Inc.

OBK

Origin Bancorp Inc.

HOLD

Current Price

$50.14

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$29.46

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBK
AGIO
Founded
1912
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
OBK
AGIO
Price
$50.14
$29.46
Analyst Decision
Strong Buy
Buy
Analyst Count
6
8
Target Price
$46.67
$38.88
AVG Volume (30 Days)
101.5K
803.6K
Earning Date
04-22-2026
04-29-2026
Dividend Yield
2.13%
N/A
EPS Growth
N/A
N/A
EPS
0.89
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
$26.43
$76.75
Revenue Next Year
$5.79
$170.73
P/E Ratio
$55.69
N/A
Revenue Growth
N/A
N/A
52 Week Low
$32.13
$22.24
52 Week High
$49.72
$46.00

Technical Indicators

Market Signals
Indicator
OBK
AGIO
Relative Strength Index (RSI) 68.02 55.27
Support Level $46.28 $26.71
Resistance Level N/A $29.64
Average True Range (ATR) 0.97 1.43
MACD 0.21 0.14
Stochastic Oscillator 99.88 75.31

Price Performance

Historical Comparison
OBK
AGIO

About OBK Origin Bancorp Inc.

Origin Bancorp Inc is a financial holding company that provides personalized, relationship banking to businesses, municipalities, and personal clients in the communities it serves. The company offers a broad range of financial services and operates more than 56 locations in Dallas/Fort Worth, East Texas, Houston, North Louisiana, Mississippi, South Alabama, and the Florida Panhandle. It also provides insurance agency products and services through its wholly owned insurance agency subsidiary. The company operates in one business segment, community banking, and is mainly engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: